Home » Stocks » TTPH

Tetraphase Pharmaceuticals, Inc. (TTPH)

Jul 28, 2020 - TTPH was delisted after being acquired by LJPC
Stock Price: $2.20 USD 0.00 (0.00%)
Updated Jul 28, 2020 12:00 AM EDT
Market Cap 16.07M
Revenue (ttm) 7.86M
Net Income (ttm) n/a
Shares Out 7.26M
EPS (ttm) -13.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Jul 28, 2020
Last Price $2.20
Previous Close $2.20
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.18 - 2.27
Day's Volume 0
52-Week Range 0.56 - 8.60

News

Hide News
Forbes - 6 months ago

As the virus spreads, if you’re looking to bet against the market or hedge, our deep learning algorithms paired with out Artificial Intelligence (“AI”) data has some Top Shorts named for you t...

Other stocks mentioned: BCRX, ECOR, PDSB, CRDF
Forbes - 6 months ago

We will have to wait to see if the wind is truly changing to the bears, or if the bulls can come back throughout the day – either way, our deep learning algorithms paired with Artificial Intel...

Other stocks mentioned: FCEL, IDN, MNKD
Business Wire - 6 months ago

SAN DIEGO & WATERTOWN, Mass.--(BUSINESS WIRE)--La Jolla Pharmaceutical Company, which is dedicated to the development and commercialization of innovative therapies that improve outcomes in pat...

Benzinga - 6 months ago

The bidding war for Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) seems to be far from over.

Business Wire - 6 months ago

WATERTOWN, Mass.--(BUSINESS WIRE)--Tetraphase Pharmaceuticals, Inc. (Nasdaq:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for inje...

Forbes - 6 months ago

With the S&P 500, Nasdaq, and Dow going positive today, we link the markets are overextended. Our deep learning and AI has identified several Top Shorts today for you to hedge your portfolio w...

Other stocks mentioned: BLNK, COCP, ECOR
Forbes - 7 months ago

This week has been a successful one for markets, with the S&P 500 entering positive territory on the year. If you’re looking to hedge the rally, our deep learning algorithms have identified se...

Other stocks mentioned: BLNK, COCP, DMTK
Zacks Investment Research - 8 months ago

Tetraphase (TTPH) delivered earnings and revenue surprises of 19.63% and -28.37%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 8 months ago

Shares of nano-cap Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which have never really recovered from a steep sell-off triggered by an adverse clinical readout in late 2015, are surging Thu...

Zacks Investment Research - 8 months ago

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 8 months ago

During Tetraphase's (TTPH) upcoming Q1 earnings call, investor focus will be on management's update on the company's pending merger with AcelRx Pharmaceuticals.

Zacks Investment Research - 10 months ago

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Larry Edwards on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Tetraphase (TTPH) delivered earnings and revenue surprises of 4.31% and 115.48%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Larry Edwards on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Tetraphase (TTPH) delivered earnings and revenue surprises of -10.53% and -49.62%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Tetraphase (TTPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Tetraphase Pharmaceuticals' (TTPH) CEO Guy Macdonald on Q1 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Tetraphase (TTPH) delivered earnings and revenue surprises of 7.69% and -34.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 1 year ago

Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Guy Macdonald on Q4 2018 Results - Earnings Call Transcript

About TTPH

Tetraphase Pharmaceuticals, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections. It conducted Phase III clinical trials with Xerava through investigating Gram-negative infections treated with Xerava (IGN... [Read more...]

Industry
Biotechnology
IPO Date
Mar 20, 2013
CEO
Larry Edwards
Employees
67
Stock Exchange
NASDAQ
Ticker Symbol
TTPH
Full Company Profile

Financial Performance

In 2019, TTPH's revenue was $7.38 million, a decrease of -60.98% compared to the previous year's $18.90 million. Losses were -$70.09 million, -2.87% less than in 2018.

Financial Statements